Bafetinib (INNO-406)

Catalog No. A10119

Bafetinib (INNO-406)是一种双重Bcr-Abl/Lyn酪氨酸激酶抑制剂。

Product Citations

Li T, .et al. Bruton's tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma, Oncogene, 2018, Nov;37(47):6180-6194 PMID: 30013190
S. Dallari, .et al. Src family kinases Fyn and Lyn are constitutively activated and mediate plasmacytoid dendritic cell responses, Nat Commun, 2017, 8: 14830 PMID: 28368000
Andrea Haerzschel, .et al. BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia, Ann Hematol, 2016, 95(12): 1979-1988 PMID: 27542958
Magdalena Winiarska, .et al. Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies, MAbs., 2014, 6(5): 1300-1313. PMID: 25517315

Technical details

Catalog Num	A10119
M. Wt	576.6
Formula	C30H31F3N8O
Purity	>98%
Storage	at -20°C 3 years Powder
CAS No.	859212-16-1
Synonyms	NS-187
SMILES	CC1=C(C=C(C=C1)NC(=O)C2=CC(=C(C=C2)CN3CC[C@@H](C3)N(C)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CN=C5

Biological Activity

Bafetinib (INNO-406)是一种双重Bcr-Abl/Lyn酪氨酸激酶抑制剂。

Targets

Abl (Cell-free assay)	Lyn (Cell-free assay)
5.8 nM	19 nM

Solubility *

In vitro (25°C)	DMSO	92 mg/mL (159.55 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	0.5% methylcellulose+0.2% Tween 80	28 mg/mL
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	17.34 mL	86.72 mL	173.43 mL
0.5 mM	3.47 mL	17.34 mL	34.69 mL
1 mM	1.73 mL	8.67 mL	17.34 mL
5 mM	0.35 mL	1.73 mL	3.47 mL

*The above data is based on the productmolecular weight 576.6 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.